At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Hypofractionated Radiation Therapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Hypofractionated Radiation Therapy for Ductal Breast Carcinoma In Situ and 8 related conditions. Completed, enrolled 102 participants across 1 site.
Detailed Summary
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuctal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartDec 2017
Primary CompletionAug 2022
Study CompletionJun 2025
TodayJul 2026
First PostedNov 17, 2017
Enrollment StartDec 12, 2017
Primary CompletionAug 30, 2022
Study CompletionJun 26, 2025
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 8.6 years ago
Interventions
Hypofractionated Radiation Therapyradiation
Undergo hypofractionated radiation therapy